A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

This study tests a new treatment called SV-102 — part of a platform called SYNC-T therapy — in men with metastatic castration-resistant prostate cancer (mCRPC), meaning prostate cancer that has spread and is no longer responding to hormone-lowering treatments. SYNC-T is a novel approach that combines tumor removal with immune activation to create a personalized in-body immune response against the cancer. This early study focuses on safety, tolerability, and early signs of effectiveness. **You may be eligible if...** - You are a man aged 18 or older with confirmed advanced prostate cancer (adenocarcinoma) - Your testosterone is at very low (castrate) levels from hormone therapy - Your cancer progressed after one or more approved hormone-blocking drugs (like enzalutamide or abiraterone), with or without prior taxane chemotherapy - You have not received more than 3 prior lines of therapy - You are in good enough health to undergo sedation or general anesthesia - Your heart has been cleared by a cardiac assessment within the past 2 months - Your ECOG score is less than 3 **You may NOT be eligible if...** - You have significant organ damage or unresolved side effects from prior treatments - Your last cancer treatment (excluding hormones) was less than 28 days ago - You are unwilling to use contraception during and after treatment Talk to your doctor to see if this trial is right for you.